ClinicalTrials.gg
CompletedNCT01278797Updated Mar 28, 2014Results posted

Telmisartan and Amlodipine Versus Monocomponent Tablets

A Phase 1 interventional study of Telmisartan/Amlodipine Combination Tablet and Amlodipine Monocomponent in Hypertension, sponsored by Boehringer Ingelheim. Completed at 1 site in Canada. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-03-28.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 122 studies in Hypertension by Boehringer Ingelheim — 1 open to participants now, 1 under way, 1 of them phase 3. Hypertension · Boehringer Ingelheim.

Enrollment
67th of 74
28 · median 381
Started
2011
with 5 others
Phase 1
Only one
of the 122
Registered
61st of 122
by date

Among the 122 studies in Hypertension by Boehringer Ingelheim, this one is the 67th largest by enrollment of the 74 interventional ones that give a count, is one of 6 that started in 2011, is the only one in phase 1, and was the 61st registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 122 studies in Hypertension by Boehringer Ingelheim is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Hypertension by Boehringer Ingelheim, or all of them as a file.
02

Study summary

This study will be an open-label, randomized, two-treatment, two-period, two-sequence crossover study to evaluate the bioequivalence of the amlodipine component of Boehringer Ingelheim Pharma GmbH \& Co. KGs 80 mg telmisartan/10 mg amlodipine fixed dose combination tablet to the corresponding mono-component amlodipine tablets, 10 mg (Pfizers Norvasc).

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy, non-smoking, male and/or /surgically sterile female subjects from 18 to 55 years of age.
  2. Females who participate in this study must either:

    1. be post-menopausal for at least 1 year (no menstrual cycle for 12 consecutive months) and deemed post-menopausal by a physician based on screening clinical laboratory tests (Follicle stimulating hormone (FSH) and Luteinising Hormone (LH)
    2. provide proof of surgical sterility.
  3. (BMI) greater than or equal to 19.0 and less than or equal to 30.0 kg/m2.
  4. No findings in vital signs measurements and systolic blood pressure greater than or equal to 110 mmHg at screening.
  5. No clinically significant abnormal laboratory values.
  6. No clinically significant findings in a 12-lead (ECG) and the time between the P and the R waves on the ECG (PR interval) less than or equal to 200 ms at screening.
  7. Have no significant diseases.
  8. Be informed of the nature of the study and give written consent prior to receiving any study procedure.
  9. Have no clinically significant findings from a physical examination.

Exclusion criteria

Exclusion criteria:

  1. Known history or presence of any medical condition.
  2. Known or suspected carcinoma.
  3. History or presence of cardiovascular dysfunction (e.g. increased angina, myocardial infarction, outflow obstruction, congestive heart failure).
  4. History of clinically significant hypotension.
  5. Presence of hepatic dysfunction.
  6. Known history or presence of galactose or fructose intolerance, sucrase-isomaltase insufficiency, Lapp lactase insufficiency, galactosemia, or glucose-galactose malabsorption syndrome.
  7. History of gastrointestinal tract surgery (appendectomy is permitted).
  8. Presence of clinically significant gastrointestinal disease or history of malabsorption within the last year.
  9. Presence of a medical condition requiring regular medication (prescription and/or over-the-counter) with systemic absorption.
  10. History of drug or alcohol addiction requiring treatment.
  11. Positive test result for serum hCG consistent with pregnancy (females only), , surface antigen, or antibody.
  12. Positive test result for urine drugs of abuse (cannabinoids, opiates, amphetamines, cocaine, phencyclidine, tricyclic antidepressants, barbiturates, methadone, and benzodiazepines) or urine cotinine.
  13. Difficulty fasting or consuming standard meals.
  14. Females who are pregnant, lactating, or likely to become pregnant during the study.
  15. Does not tolerate venipuncture.
  16. Use of tobacco or nicotine-containing products within 6 months prior to drug administration.
  17. On a special diet within 30 days prior to drug administration (e.g. liquid, protein, raw food diet).
  18. Participated in another clinical trial or received an product within 30 days prior to drug administration.
  19. Donation or loss of whole blood:

    1. Great than or equal to 50 mL and less than or equal to 499 mL within 30 days prior to dosing
    2. greater than or equal to 500 mL within 56 days prior to dosing.
  20. Females who have used hormonal within 6 months prior to drug administration.
  21. Have had a tattoo or body piercing within 30 days prior to dosing.
  22. Known history or presence of or idiosyncratic reaction to telmisartan, amlodipine, or any other drug substances with similar activity.
  23. Use of any drugs known to:

    1. induce (e.g. barbiturates, carbamazepine, phenytoin, , omeprazole)
    2. inhibit (e.g. antidepressants (Selective Seratonin Reuptake Inhibitor (SSRI)I), cimetidine, diltiazem, macrolides, imidazoles, neuroleptics, verapamil, fluoroquinolones, antihistamines) hepatic drug metabolism within 30 days prior to drug administration.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single
Enrollment
28 participants (actual)

Study arms

  • Active comparator
    Telmisartan/Amlodipine Fixed Dose

    Telmisartan/Amlodipine medium fixed dose combination tablet once daily.

    Drug: Telmisartan/Amlodipine Combination Tablet

  • Active comparator
    Amlodipine Monocomponent

    Amlodipine Monocomponent 10mg tablet once daily

    Drug: Amlodipine Monocomponent

Interventions

  • DrugTelmisartan/Amlodipine Combination Tablet

    Combination Tablet

  • DrugAmlodipine Monocomponent

    Active Comparator

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve of Plasma Amlodipine From 0 to 72 Hours (AUC72)

    Area under the analyte concentration versus time curve from time zero to 72 hours as calculated by the linear trapezoidal method

    Time frame: Day 1, Day 22

  2. Maximum Observed Plasma Concentration (Cmax) of Amlodipine

    Time frame: Day 1, Day 22

Secondary outcomes

  1. Time of Maximum Concentration of Amlodipine (TMAX)

    Time of maximum measured amlodipine concentration over the zero to 72 hour sampling period

    Time frame: Day 1, Day 22

07

Results

Posted Mar 16, 2012

Participant flow

Period 1
Participant flow — Period 1
MilestoneTelm/Amlo 80 mg/10 mg First, Then Telm 80 mg + Amlo 10 mgTelm 80 mg + Amlo 10 mg First, Then Telm/Amlo 80 mg/10 mg
Started1414
Completed1313
Not completed11
Withdrew: Adverse event01
Withdrew: Protocol violation10
Washout Period of 21 Days
Participant flow — Washout Period of 21 Days
MilestoneTelm/Amlo 80 mg/10 mg First, Then Telm 80 mg + Amlo 10 mgTelm 80 mg + Amlo 10 mg First, Then Telm/Amlo 80 mg/10 mg
Started1313
Completed1313
Not completed00
Period 2
Participant flow — Period 2
MilestoneTelm/Amlo 80 mg/10 mg First, Then Telm 80 mg + Amlo 10 mgTelm 80 mg + Amlo 10 mg First, Then Telm/Amlo 80 mg/10 mg
Started1313
Completed1313
Not completed00

Outcome measures

PrimaryArea Under the Concentration-time Curve of Plasma Amlodipine From 0 to 72 Hours (AUC72)

Area under the analyte concentration versus time curve from time zero to 72 hours as calculated by the linear trapezoidal method

Time frame:
Day 1, Day 22
Reported as:
Mean · nanograms*hour/milliliter
Area Under the Concentration-time Curve of Plasma Amlodipine From 0 to 72 Hours (AUC72)
nanograms*hour/milliliterTelm/Amlo 80 mg/10 mgTelm 80 mg + Amlo 10 mg
Area Under the Concentration-time Curve of Plasma Amlodipine From 0 to 72 Hours (AUC72)260.7971 ± 60.8717276.6315 ± 66.1935
Statistical analysis
  • Telm/Amlo 80 mg/10 mg vs Telm 80 mg + Amlo 10 mg · ANOVA · p = 0.005 · Test/reference ratio of geometric means: 94.51 · 90% CI 91.60 to 97.51ANOVA was applied to log-transformed AUC72 and Included treatment, sequence, period and subject-within-sequence effects.
PrimaryMaximum Observed Plasma Concentration (Cmax) of Amlodipine
Time frame:
Day 1, Day 22
Reported as:
Mean · nanograms/milliliter
Maximum Observed Plasma Concentration (Cmax) of Amlodipine
nanograms/milliliterTelm/Amlo 80 mg/10 mgTelm 80 mg + Amlo 10 mg
Maximum Observed Plasma Concentration (Cmax) of Amlodipine6.7465 ± 1.33547.2258 ± 1.6549
Statistical analysis
  • Telm/Amlo 80 mg/10 mg vs Telm 80 mg + Amlo 10 mg · ANOVA · p = 0.0093 · Test/reference ratio of geometric means: 94.10 · 90% CI 90.70 to 97.63ANOVA was applied to log-transformed CMAX and Included treatment, sequence, period and subject-within-sequence effects.
SecondaryTime of Maximum Concentration of Amlodipine (TMAX)

Time of maximum measured amlodipine concentration over the zero to 72 hour sampling period

Time frame:
Day 1, Day 22
Reported as:
Mean · hours
Time of Maximum Concentration of Amlodipine (TMAX)
hoursTelm/Amlo 80 mg/10 mgTelm 80 mg + Amlo 10 mg
Time of Maximum Concentration of Amlodipine (TMAX)6.69 ± 1.956.12 ± 1.40
Statistical analysis
  • Telm/Amlo 80 mg/10 mg vs Telm 80 mg + Amlo 10 mg · ANOVA · p = 0.153 · Mean difference (final values): 0.58ANOVA was applied to TMAX and Included treatment, sequence, period and subject-within-sequence effects.

Adverse events

Collected over 30 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Telm/Amlo 80 mg/10 mg—0/27 (0%)3/27 (11.1%)
Telm 80 mg + Amlo 10 mg—0/27 (0%)3/27 (11.1%)
Most frequent other events
Most frequent other events
EventTelm/Amlo 80 mg/10 mgTelm 80 mg + Amlo 10 mg
Blood urine presentRenal and urinary disorders1/272/27
HeadacheNervous system disorders2/271/27
Urine abnormalityRenal and urinary disorders0/272/27

Baseline characteristics

Age, Continuous
Age, Continuous(years)Entire Study Population
Mean39 ± 9
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female1
Male27
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Entire Study Population
Hispanic/Latino7
Asian3
Black/African American6
White12
Height
Height(centimeter)Entire Study Population
Mean173.1 ± 7.1
Weight
Weight(kilogram)Entire Study Population
Mean80.3 ± 9.9
Body Mass Index
Body Mass Index(kilogram / square meter)Entire Study Population
Mean26.7 ± 2.5
08

Study locations

1 site
  • 1235.41.0001 Boehringer Ingelheim Investigational Site
    Toronto, Ontario, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011 and a primary completion of Feb 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2011
First posted
Jan 19, 2011
Start
Jan 2011
Primary completionActual
Feb 2011
Results first posted
Mar 16, 2012
Last update
Mar 28, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01278797
First posted
Jan 19, 2011
Start date
Jan 2011
Primary completion
Feb 2011
Results posted
Mar 16, 2012
Last update
Mar 28, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion